Tag Archives: MTC

PR Newswire

Paige Applauded by Frost & Sullivan for its Leading AI-based Computational Pathology Offering that Enables Fast and Accurate Cancer Diagnoses

Leave a comment

Paige leveraged the world’s largest dataset in pathology to develop an unparalleled computation pathology offering

SANTA CLARA, California, July 8, 2020 — Based on its recent analysis of the North American AI-based digital pathology market, Frost & Sullivan recognizes Paige with the 2020 North American Enabling Technology Leadership Award for its disruptive product offering.

Paige
Paige

Paige has developed robust machine learning models for computational pathology for detecting cancer subtypes, thereby enhancing the diagnosis capability of pathologists worldwide. Paige’s AI-based technology was developed and tested on over 100,000 de-identified, digitized slide images from more than 16,000 cancer patients. The deep learning algorithms detected prostate cancer, skin cancer, and breast cancer with near-perfect accuracy.   

“Paige’s AI algorithms validated against the world’s largest dataset in pathology makes it the most trustworthy best in class pathology diagnosis solution,” said Debarati Sengupta, Industry Analyst, Frost & Sullivan. “Paige’s technology eliminates the need to curate datasets, which is time-consuming and expensive. Paige’s AI based pathology offering enables pathologists to make a fast and accurate diagnosis of even the most complex and difficult to interpret slides.”

The Paige offering consists of general and organ-specific products that provide rapid diagnostic stratification, cancer detection, tumor segmentation, and prediction of treatment response, and overall survival. Its algorithms form a portfolio of AI-based digital diagnostics and biomarkers to help pathologists provide diagnoses. For security purposes, all datasets used to build the products were de-identified, and any protected health information or label text was removed.

Notably, Paige’s computational pathology offering received the Breakthrough Device designation by the US Food and Drug Administration (FDA) in 2019, making it the first such device for cancer diagnosis. Furthermore, it began commercializing in 2019 following its CE mark approval for Paige Prostate, which is a first-to-market prostate cancer detection solution, and a digital pathology viewer for the primary diagnosis of any digital slide. Paige’s AI-based solutions are vendor agnostic, which helps it serve a wider pool of customers.

In 2020, it formed a strategic partnership with Invicro LLC, a Konica Minolta company to provide its AI-based integrated pathology solutions to support Invicro’s drug discovery and development initiatives. “Paige continues to expand its footprint not just in commercial laboratories, but also in biopharmaceutical companies, positioning itself as a pioneer in AI-based digital pathology market” noted Sengupta.

Each year, Frost & Sullivan presents this award to a company that has developed a pioneering technology that not only enhances current products but also enables the development of new products and applications. The award recognizes the high market acceptance potential of the recipient’s technology.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About Frost & Sullivan
For over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Contact:
Kristen Moore
P: 210.247.3823
E: kristen.moore@frost.com

About Paige
Paige was founded in 2017 by Thomas Fuchs, Dr.Sc., and colleagues from Memorial Sloan Kettering Cancer Center.  The Company builds computational pathology products designed so patients and their care teams can make faster, more informed treatment decisions. With this new class of diagnostic devices positioned to drive the future of pathology, Paige created a platform to deliver this novel technology to pathologists to transform their workflow and increase diagnostic confidence and productivity.  Paige’s lightweight platform was purpose-built with pathologists to offer an intuitive user experience, minimize IT burden and costs while ensuring patient safety and data privacy. Our products deliver insights to pathologists so they can arrive efficiently at more precise diagnoses for patients. Paige is the first and only company to receive FDA breakthrough designation for computational pathology products.

For additional information, please visit:  https://www.Paige.ai  Twitter and LinkedIn

Media Contact:
NRPR Group
Nicole Rodrigues
(650) 815-5069
nicole@nrprgroup.com

Related Links :

http://www.frost.com

PR Newswire

Xovis Multiplies Your Options in One Fell Swoop

Leave a comment

Two new AI features for in-store analytics made possible by Xovis 3D sensors

ZOLLIKOFEN, Switzerland, July 2, 2020 — When their ordinary "all-in-a-day’s-work" became extraordinary, Xovis ramped up their R&D to solve unforeseen challenges. Today, the company proudly presents two new AI features for their 3D people counting sensors: Face Mask Detection and View Direction. While View Direction had been hinted at in January this year, Face Mask Detection has sprung up out of the current situation with COVID-19. Xovis hopes that this will help their customers stay on top of public health regulations. The company’s innovative and GDPR compliant technology becomes the only kind to detect face masks directly on 3D sensors.

The Xovis Face Mask Detection
The Xovis Face Mask Detection

 

The Xovis View Direction
The Xovis View Direction

As Xovis Head of Retail Anne Wyder explains, "COVID-19 has made face masks compulsory in many public places; we have responded by developing a new AI feature for our sensors to recognize whether or not face masks are in fact being worn. In a bid to help businesses adhere to public health regulations, this new software plugin for Face Mask Detection will be free of charge until the end of the year for our integrator partners working with the Xovis Cloud Account." 

Despite COVID-19, and at the same time because of the global crisis that has ensued, Xovis is actively providing technological solutions for both occupancy and physical distancing management. As Xovis CPO Christian Studer puts it: "We have been busy – we’ve not only finished development of the much-anticipated View Direction plugin for in-store analytics, but in an agile response to changing market demands also stepped up to the plate and created something extra in our firmware for our customers. Both Face Mask Detection and View Direction features provide deeper insight into customer behavior – the analysis of which has become more important than ever before."

As the undisputed innovator of people flow technology based on 3D stereovision sensors, Xovis is committed to bringing the best products and services to customers and partners alike. Because people count.

See how Xovis detects Face Masks

Read how Xovis View Direction works

Click here for more about Xovis Physical Distancing Solutions

Photo – https://techent.tv/wp-content/uploads/2020/07/xovis-multiplies-your-options-in-one-fell-swoop-3.jpg  
Photo – https://techent.tv/wp-content/uploads/2020/07/xovis-multiplies-your-options-in-one-fell-swoop.jpg  
Logo – https://techent.tv/wp-content/uploads/2020/07/xovis-multiplies-your-options-in-one-fell-swoop-2.jpg

Company Contact
Xovis
Industriestrasse 1
3052 Zollikofen
Switzerland
+41-32-342-04-70
info@xovis.com

Media Contact
Christian Studer, CPO
+41-32-508-35-41
christian.studer@xovis.com

Related Links :

https://www.xovis.com/

PR Newswire

Clarivate Introduces Next Generation Insights Platform with Cortellis Generics Intelligence

Leave a comment

Enhanced Newport platform allows for comprehensive and accurate analysis of market, API and patent data from a single application

LONDON, July 1, 2020 — Clarivate Plc (NYSE:CCC), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the launch of Cortellis Generics Intelligence™ to enable generics companies and Active Pharmaceutical Ingredient (API) manufacturers to make timely and more informed data-driven decisions as they seek to drive business growth, identify new markets, products and partners, defend market share and more. The modern, intuitive platform enables sourcing, business development, portfolio and intellectual property teams within an organization to make data-driven decisions – all from a single application.


Cortellis Generics Intelligence powered by Clarivate Research Intelligence Cloud replaces and enhances the well-known Newport platform from Clarivate. It includes new intuitive search capabilities together with expertly curated data on market performance, patents and litigation, and manufacturers to assist finished dose manufacturers, API manufacturers, and pharmaceutical marketers in their pursuit to successfully launch generic drugs and maintain a steady supply chain.

This comprehensive database collates crucial market, API, and patent data, including sales and consumption data, product launches, company information, Paragraph IV patent challenges, API suppliers’ regulatory filings and more. With seamless connectivity to the broader Cortellis suite of life science intelligence solutions, researchers will have comprehensive access to high-quality drug development, clinical trial, deal-making and regulatory intelligence.

Keith Collier, Senior Vice President of Product Management, Clarivate said: "The generics industry is extremely competitive with a high degree of uncertainty and complexity in bringing a drug to market or identifying APIs with the most market potential. All teams within a company are involved in making decisions that will ultimately impact their company’s achievements and risk making the wrong decision based on partial data. Cortellis Generics Intelligence is the most comprehensive source of market performance, patent and manufacturing data, allowing generics and API companies to easily connect the dots between key areas of intelligence, so they can validate their strategy with the assurance they haven’t missed any critical considerations. Ultimately, this will allow them to quickly shift from market research and assessment to actually implementing their strategic priorities."

According to The Centre for Medicines Research (CMR) International, over the next seven years, 114 products are predicted to lose exclusivity and become generic within the U.S. ― 8% of which are currently blockbuster products1. This number is scheduled to increase each year from now until 2022. Due to high demand within the blockbuster space, selecting the right drug for investment requires precision. The number of Abbreviated New Drug Application (ANDA) final approvals granted by the FDA to Indian- and U.S.- headquartered companies saw a marked decrease in 2018, further supporting the need to identify the right drugs for investment to ultimately secure ANDA approval2. In addition, the number of products exposed to Paragraph IV challenges in the U.S. has continued to rise over the past four years3, indicating that more companies are looking to launch generic drugs around the world, which heightens competition. Similar dynamics are in play in other major markets around the world. These points reinforce the need for greater accuracy early in the generics lifecycle to develop a validated launch strategy and identify less promising portfolio candidates earlier – enabling the most effective use of time and resources.

Cortellis Generics Intelligence is comprised of data spanning more than 64,000 small molecules and biologics, 72,000 manufacturers and marketers, 1.1 million worldwide patents, 62,000 regulatory documents across 25+ countries, and more. Additional analytics and functionality will continue to be added throughout 2020 and 2021 to further aid with generics companies’ strategies and decision-making. The data will continue to be updated daily and expand into additional analytics to support market share analysis, the impact of litigation on generic launches and competitive assessments.

To learn more about Cortellis Generics Intelligence, visit http://www.clarivate.com/genericsintelligence.

About Clarivate

Clarivate™ is a global leader in providing trusted information and insights to accelerate the pace of innovation. We offer subscription and technology-based solutions coupled with deep domain expertise that cover the entire lifecycle of innovation – from foundational research and ideas to protection and commercialization. Today, we’re setting a trail-blazing course to help customers turn bold ideas into life-changing inventions. Our portfolio consists of some of the world’s most trusted information brands, including the Web of Science™, Cortellis™, Derwent™, CompuMark™, MarkMonitor™ and Techstreet™. For more information please visit www.Clarivate.com.

Forward-Looking Statements
This press release and oral statements included herein may contain forward-looking statements regarding Clarivate. Forward-looking statements provide Clarivate’s current expectations or forecasts of future events and may include statements regarding results, anticipated synergies and other future expectations. These statements involve risks and uncertainties including factors outside of Clarivate’s control that may cause actual results to differ materially. Clarivate undertakes no obligation to update or revise the statements made herein, whether as a result of new information, future events or otherwise.

1 Clarivate Analytics (2019), 2019 CMR International Pharmaceutical R&D Factbook, https://discover.clarivate.com/2019CMRFactbook 
2 Clarivate Analytics (2019), 2019 CMR International Pharmaceutical R&D Factbook, https://discover.clarivate.com/2019CMRFactbook
3 Clarivate Analytics (2019), 2019 CMR International Pharmaceutical R&D Factbook, https://discover.clarivate.com/2019CMRFactbook 

Logo – https://techent.tv/wp-content/uploads/2020/07/clarivate-introduces-next-generation-insights-platform-with-cortellis-generics-intelligence.jpg

Related Links :

http://www.Clarivate.com

PR Newswire

Sweeping Workplace Changes Expected in a Post-pandemic World, Says Research From The Adecco Group

2 Comments

Businesses and workers call for greater flexibility, questions raised over the hours-based contract, and a new empathetic leadership profile emerges

ZURICH, June 30, 2020 —

  • Workers demand greater flexibility after coronavirus, with a 50/50 split of remote and office time confirmed as the universal ideal
  • Questions raised over the hours-based contract, with 69% saying contracts should be based on results delivered rather than hours worked
  • Boom in digital skills an unintended consequence of lockdown, with tech knowhow improving for six in 10 (61%), and two thirds (69%) eager for further digital upskilling post-pandemic
  • Leaders need to reinvent themselves as more emotionally intelligent, but they are not prepared, as less than half felt equipped to support employees holistically during the pandemic

The coronavirus pandemic has resulted in pivotal shifts in attitudes and expectations among workers and leaders, as both call for permanent changes in how and where we work, workplace relationships and future skills, according to new research from the Adecco Group.

The Adecco Group, the world’s leading HR solutions company, today unveiled the results of its latest study, Resetting Normal: Defining the New Era of Work, examining the expected short- and long-term impact of the pandemic on resetting workplace norms. Fieldwork was conducted in May 2020, with 8,000 office-based respondents (aged 18-60) across Australia, France, Germany, Italy, Japan, Spain, the UK and the USA.

The Adecco Group’s Chief Executive Officer, Alain Dehaze, said: “The world of work will never return to the ‘normal’ we knew before the pandemic struck. The sudden and dramatic change in the workplace landscape has accelerated emerging trends such as flexible working, high-EQ leadership, and re-skilling, to the point where they are now fundamental to organisational success. As many countries emerge from the acute crisis phase of the pandemic, employers have an opportunity to ‘hit reset’ on traditional workplace practices – many of which have remained largely unchanged since the industrial revolution. This research highlights that employee attitudes have shifted and gaps between workforce expectations and entrenched labour market processes have been exposed. As we step into the new era of work, now is the time to establish better norms that will enable a holistically healthy, productive and inclusive workforce into the future.”

Key research highlights:

The research revealed that the working world is ready for a new “hybrid” model, with three quarters (74%) of workers surveyed saying a mix of office-based and remote working is the best way forward. The universal ideal of spending half (51%) of their time in the office and half working remotely (49%) transcends geographies, generations and parental status. And company executives agree, with almost eight in ten (77%) C-suite leaders saying businesses will benefit from increased flexibility.

Another stark finding could signal the end of the hours-based contract and 40-hour week. More than two thirds (69%) of workers are in favour of “results-driven work,” whereby contracts are based on delivering against business needs rather than working a set number of hours. A high proportion of C-suite executives (74%) agree that the length of the working week should be revisited.

The pandemic has also demanded a new set of leadership competencies and these expectations are expected to accelerate a reinvention of the modern-day leader. Emotional intelligence has clearly emerged as the defining trait of today’s successful manager, but the soft skills gap is evident. Over a quarter (28%) of those questioned said their mental wellbeing had worsened due to the pandemic, with only 1 in 10 rating their managers highly on their ability to support their emotional health.   

In a similar nature to flexible working, the findings demonstrate a universal appetite for mass upskilling. Six in 10 say their digital skills have improved during lockdown, while a further two thirds (69%) are looking for further digital upskilling in the post-pandemic era. A broad range of skills development were identified as important by the workforce, including managing staff remotely (65%), soft skills (63%) and creative thinking (55%).

Finally, the findings highlighted the importance of sustaining trust in the new working world. Companies have risen to the challenge of supporting their people during the crisis, and as a result, trust in corporations has increased. In fact, 88% say that their employer met or exceeded their expectations in adapting to the challenges of the pandemic. And with this increased trust comes increased expectations. While the future of work is a collective responsibility, 80% of employees believe their employer is responsible for ensuring a better working world post-COVID and resetting norms, compared with 73% who say the government is responsible, 72% who agree it is an individual responsibility, and 63% who believe it is in the hands of labour unions.

For more information: 

  • Download the Resetting Normal: Defining the New Era of Work full report here.
  • Follow us on social #ResetNormal for updates 

About the Adecco Group

The Adecco Group is the world’s leading HR solutions company. We believe in making the future work for everyone, and every day enable more than 3.5 million careers. We skill, develop, and hire talent in 60 countries, enabling organisations to embrace the future of work. As a Fortune Global 500 company, we lead by example, creating shared value that fuels economies and builds better societies. Our culture of inclusivity, entrepreneurship and teamwork empowers our 35,000 employees and we are proud to have been consistently ranked one of the ‘World’s Best Workplaces’ by Great Place to Work®. The Adecco Group AG is headquartered in Zurich, Switzerland (ISIN: CH0012138605) and listed on the SIX Swiss Exchange (ADEN) and powered by nine global brands: Adecco, Adia, Badenoch & Clark, General Assembly, Lee Hecht Harrison, Modis, Pontoon, Spring Professional and Vettery.

adeccogroup.com
Facebook: facebook.com/theadeccogroup
Twitter: @AdeccoGroup

Logo – https://techent.tv/wp-content/uploads/2020/06/sweeping-workplace-changes-expected-in-a-post-pandemic-world-says-research-from-the-adecco-group.jpg

For further information please contact:
The Adecco Group Press Office
media@adeccogroup.com
+41-(0)-44-878-87-87

Related Links :

https://www.adeccogroup.com

PR Newswire

PolyU collaborates with Macau University of Science and Technology to advance diagnosis of COVID-19 pneumonia

Leave a comment

HONG KONG, June 15, 2020 /PRNewswire/ — COVID-19 is taking its toll on the world, affecting more than 200 countries and regions. In the face of a surge in cases, rapid diagnosis and identification of high-risk patients for early intervention is crucial for controlling the pandemic. The Hong Kong Polytechnic University (PolyU) is committed to the fight against COVID-19 and has been collaborating with various partners in the prevention and control of the disease. PolyU today announced the launch of a new AI system jointly developed with the Macau University of Science and Technology (M.U.S.T.) in conjunction with other Chinese institutions, to assist in the rapid diagnosis of COVID-19 pneumonia. This research was published in the prestigious international journal Cell, in a paper entitled “Clinically Applicable AI System for Accurate Diagnosis, Quantitative Measurements, and Prognosis of COVID-19 Pneumonia Using Computed Tomography” (link).

(From left) Dr Johnson LAU, Adjunct Professor of the Department of Applied Biology and Chemical Technology of PolyU; Prof. Manson FOK, Faculty of Medicine of Macau University of Science and Technology (M.U.S.T.); Prof. Alexander WAI, Deputy President and Provost of PolyU; and Prof. Kang ZHANG, Faculty of Medicine of M.U.S.T. introduce a new AI system for rapid and accurate diagnosis of COVID-19 pneumonia.
(From left) Dr Johnson LAU, Adjunct Professor of the Department of Applied Biology and Chemical Technology of PolyU; Prof. Manson FOK, Faculty of Medicine of Macau University of Science and Technology (M.U.S.T.); Prof. Alexander WAI, Deputy President and Provost of PolyU; and Prof. Kang ZHANG, Faculty of Medicine of M.U.S.T. introduce a new AI system for rapid and accurate diagnosis of COVID-19 pneumonia.

The novel AI-assisted diagnostic system, based on computed tomography (CT) chest imaging, can efficiently distinguish COVID-19 pneumonia from other viral pneumonia, and predict the severity level in 20 seconds, with an accuracy of up to 90% or above. It assists radiologists and physicians in performing a quick diagnosis, especially when the health system is overloaded.

According to Professor Kang ZHANG of the Faculty of Medicine of M.U.S.T. — the first author of the research paper, the research team used a large CT database of 3,777 patients to train and test the AI system to differentiate novel coronavirus pneumonia (NCP) from other common pneumonia and normal controls. This system is able to provide accurate clinical prognosis that can aid clinicians when considering appropriate early clinical management and appropriate resource allocation. It has been developed to assist global clinicians in combating COVID-19.

Dr Johnson LAU, Adjunct Professor of the Department of Applied Biology and Chemical Technology of PolyU, explained that the AI team uses deep learning, semantic segmentation and multiple neural network architectures to create an accurate AI diagnostic system comprising texture analysis, quantitative measurements and diagnosis classification. In addition, based on the international standard for related research on lung lesions, lung, liver damage and relevant clinical indicators, they have also developed a comprehensive rating system to project the emergence of pneumonia severe lesions accurately for the follow-up treatment.

The scientists from PolyU and M.U.S.T. have also collaborated on other projects, including the seroconversion study in SARS-CoV-2 (COVID-19) patients in China, which helped pave the way for further diagnostic and therapeutic development to treat SARS-CoV-2. The study “Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China” was also recently published in another prestigious scientific journal Nature Medicine (link).

“Leveraging PolyU’s strengths and our collaborations with different research partners, we are able to contribute to the well-being of humankind. During the outbreak, we have developed a rapid automated diagnostic system to detect COVID-19 and have conducted various scientific experiments related to the pandemic,” said Professor Alexander WAI, Deputy President and Provost of PolyU. “Since the establishment of the biotechnology and translational medicine international collaborative platform in 2018, PolyU has been working closely with M.U.S.T. and other partners from the United States and the Greater Bay Area for high-impact research. Our long-term cooperation has paved the way for us to respond quickly, and to use our expertise to develop this new AI system for the diagnosis and prognosis of COVID-19.”

Professor Manson FOK, Dean of the Faculty of Medicine of M.U.S.T., remarked that this AI system had been implemented in many hospitals in different countries. M.U.S.T. is collaborating with several prominent universities including Baylor University, University of Buffalo and Stanford University to serve the US populations. He believed this application could soon be adopted in Hong Kong, more regions of Mainland China and worldwide.

COVID-19 is a new and highly contagious virus with over 7 million people infected (as of June 10). Researchers from PolyU and M.U.S.T. with their supportive partners will continue their efforts in COVID-19 research to use scientific technologies to combat this pandemic through prevention, diagnosis, treatment and control.

Photo – https://photos.prnasia.com/prnh/20200615/2830759-1?lang=0

PR Newswire

BioWorld Recognized for Excellence of Information & Intelligence to Biopharmaceutical Industry

Leave a comment

News service from Clarivate wins plethora of awards at 41st Annual SIPAwards

LONDON and PHILADELPHIA, June 10, 2020 /PRNewswire/ — BioWorld™, a part of Clarivate Plc (NYSE:CCC), a global leader in providing trusted information and insights to accelerate the pace of innovation, has been recognized for excellence in publishing by the Specialized Information Publishers Association (SIPA). BioWorld, the daily news service for biopharmaceutical and medical technology industries, is the recipient of seven SIPAwards.

BioWorld delivers actionable information and intelligence on the most innovative therapeutics and medical technologies in development. The global team reports breaking news and provides key perspectives on hundreds of therapeutics and devices in development – the companies behind those candidates, the business development transactions that evolve the markets, and the regulatory hurdles that both challenge and guard the processes.

Lynn Yoffee, News Director, BioWorld said, “Every day, we help our readers cut through the noise of information overload. Now ― more than ever ― it is increasingly vital that we continue to provide our readers with unique, compelling and quality content that enables drug and med-tech developers to make more informed decisions.”

SIPA hosts the annual SIPAwards competition to recognize excellence in editorial, marketing and product success. Now in its 41st year, the awards highlight the information and insights provided to niche audiences around the world.  BioWorld is now the recipient of 63 SIPAwards dating back to 1998, including 15 awards for its daily news service. This year it was honored in the following categories:

Best Daily Publication
For high-impact daily information.

  • First Place: BioWorld
  • Third Place: BioWorld MedTech

Best New or Relaunched Website
For outstanding website design and maneuverability within a site.

  • First Place: BioWorld and BioWorld MedTech for its entry, titled “Hello Future, Goodbye PDF,”

Best Series
For best series, based on writing, editing and design; the scope and detail of coverage in the stories; the timeliness or “exclusive” value.

Best Infographic
 For infographics that clearly and concisely present information, processes or data consistent with the subject matter, target industry and voice of the media outlet.

Best Use of Data
For work in which data plays an essential role. The work may feature any of several forms and formats, (e.g., infographics, trend analyses, blogs, interactive tools, data-based investigation) to enhance its overall effectiveness.

Best Interpretive or Analytical Reporting, Healthcare/Regulatory/Education
For excellent interpretive or analytical reporting covering the healthcare, regulatory and education sectors, with an analysis or explanation of a difficult topic or idea.

About Clarivate  

Clarivate™ is a global leader in providing trusted information and insights to accelerate the pace of innovation. We offer subscription and technology-based solutions coupled with deep domain expertise that cover the entire lifecycle of innovation – from foundational research and ideas to protection and commercialization. Today, we’re setting a trail-blazing course to help customers turn bold ideas into life-changing inventions. Our portfolio consists of some of the world’s most trusted information brands, including the Web of Science™, Cortellis™, Derwent™, CompuMark™, MarkMonitor™ and Techstreet™. For more information, please visit clarivate.com. 

Logo – https://techent.tv/wp-content/uploads/2020/06/bioworld-recognized-for-excellence-of-information-intelligence-to-biopharmaceutical-industry.jpg  

PR Newswire

icometrix launches its icompanion platform for people with multiple sclerosis

Leave a comment

LEUVEN, Belgium and CHICAGO, June 2, 2020 /PRNewswire/ — icometrix, the world leader to extract clinically meaningful data from brain scans, is proud to have launched the icompanion platform and phone application for people with multiple sclerosis on World MS Day!  icompanion is a medical device and is currently available in English, French, German, and Dutch.

To support people with multiple sclerosis, icompanion provides an easy and secure app to track symptoms, treatments, and physician visits. Users can also obtain educational information on the meaning and quality of their brain scans by uploading their MRI scans onto the platform. With this, icompanion provides a solution to log events that occur between neurologist visits, by means of day-to-day symptom-tracking and standardized questionnaires (patient-reported outcomes).

“As a neurologist, you see a patient only a couple of times a year and we know that a lot of valuable information is lost in-between,” says Dr. Helmut Butzkeuven, neurologist at the Monash University in Melbourne, and director of MSBase, the largest global multiple sclerosis registry. “To make informed clinical and treatment decisions, it is important to have a complete picture of how a patient is doing,” Dr. Butzkeuven continues. “Medical devices such as icompanion can greatly help in democratizing care, since today, patient care depends on where you live and who cares for you,” Dr. Butzkeuven concludes.

“icompanion helps me keep track of my symptoms. Even if they seem insignificant, they are crucial in helping me communicate with my physician and prepare my visits. I think it’s great that by using icompanion, my data can also support researchers in their fight against multiple sclerosis. To win this battle we need everyone’s help, and together we are stronger,” shares Roberto Paolella, living with MS for 15 years.

“Offering care based on data and objective measures is crucial to move towards more personalized and precise medicine for people with neurological disorders,” says Wim Van Hecke, CEO of icometrix. “That is why we founded icometrix and developed the CE-labeled and FDA-cleared icobrain MR and CT brain measures, which are becoming standard of care. Through icompanion, the gap between doctor visits is bridged with clinically meaningful and validated data. The seamless availability of the icompanion data to the health care provider is very important in this context,” Wim Van Hecke states.

About icometrix 
icometrix is the world leader in software solutions to obtain clinically meaningful data from brain MR and CT scans for patients with neurological conditions such as multiple sclerosis, brain trauma, epilepsy, dementia, Alzheimer’s, Parkinson’s, etc. The fully automated icobrain software from icometrix is FDA cleared and CE labeled and leverages artificial intelligence to quantify disease-specific brain structures. Today, icometrix is internationally active in over 100 clinical practices. Alongside this, icometrix works with healthcare providers and pharmaceutical companies on the evaluation of drug trials for neurological diseases.

Please visit icompanion.ms for further information.

Contact
Wim Van Hecke, CEO
wim.vanhecke@icometrix.com
+32 484 92 73 00

Press Kit 
https://tinyurl.com/ybm7tjzm

Logo – https://techent.tv/wp-content/uploads/2020/06/icometrix-launches-its-icompanion-platform-for-people-with-multiple-sclerosis.jpg

PR Newswire

ActLight Signs an Agreement on Single Photon Sensitivity Technology With Leading Sensors Company

Leave a comment

LAUSANNE, Switzerland, May 27, 2020 /PRNewswire/ — ActLight, the Swiss technology firm known for its best in class signal-to-noise ratio photodiodes, announced today that it has signed a service agreement based on its Single Photon Sensitivity technology with a leading company in the sensors market.

Single Photon Sensitivity technology
Single Photon Sensitivity technology

“Even though the terms of the agreement cannot be disclosed, we are very pleased that our innovative Single Photon Sensitivity technology attracted a leading player in the sensors field,” said Maxim Gureev, Chief Technology Officer at ActLight. “The adoption of Single Photon Avalanche Diode (SPAD) array in 3D sensing chips is growing fast. The precision of 3D sensing in applications such as smartphones, cars and smart robotics will benefit from this collaboration with our customer and our talented team of engineers is already intensively working to make it happen.”

About ActLight SA

ActLight SA, the start-up company founded in 2011 and based in Switzerland, focuses on the field of CMOS photonics by developing a new type of photodetector, the Dynamic PhotoDiode (DPD). Being a fabless company, ActLight specializes in the Intellectual Property (IP) of this area and operates primarily in the IP licensing business model.

The patented CMOS-based photonics technology allows the substantial improvement of the efficiency and accuracy of various light sensing applications, such as Time Of Flight (TOF) based range meters, vital signs monitoring, 3D/2D cameras and much more. ActLight operates in the Internet of Things (IoT) market, with a focus on mobile and wearable devices, healthcare/medtech, autonomous driving, drones and robotics.

More info about ActLight available at http://www.act-light.com

Contact: 
info@act-light.com

Photo – https://techent.tv/wp-content/uploads/2020/05/actlight-signs-an-agreement-on-single-photon-sensitivity-technology-with-leading-sensors-company.jpg
Logo – https://techent.tv/wp-content/uploads/2020/05/actlight-signs-an-agreement-on-single-photon-sensitivity-technology-with-leading-sensors-company-1.jpg

PR Newswire

Glemser Technologies and Arria NLG announce strategic partnership

Leave a comment

Together they will accelerate pharma clients’ ability to bring life-saving drugs to market through automation of medical and regulatory report writing

NEW YORK, May 20, 2020 /PRNewswire/ — Arria NLG, a leading provider of Natural Language Generation (NLG) technology, today announced a collaboration with Glemser Technologies to bring scalable automation solutions and major efficiencies to healthcare and pharmaceuticals companies. Glemser will augment its global Life Sciences Practice with a Natural Language Generation solution powered by Arria technologies.

Glemser leverages Arria NLG artificial intelligence technology to dramatically accelerate clinical trial and regulatory reporting.
Glemser leverages Arria NLG artificial intelligence technology to dramatically accelerate clinical trial and regulatory reporting.

“Partnering with Arria to provide our clients with a way to automate the writing of medical and regulatory reports was a natural choice,” says Ray Glemser, CEO. “NLG allows companies to save significant time and money while increasing scalability and efficiency. Arria’s break-through technology will transform the way our customers bring life-saving drugs to market.”

For over 30 years, Glemser has served life science clients by ensuring product quality, improving regulatory compliance, and gaining operational efficiencies. Glemser understands the unique challenges pharma companies face. Bringing a drug to market can be a difficult, costly, and drawn-out process. Pharma companies consistently have to report to regulators, governments, and consumers on drug efficacy and safety. They are constantly under pressure to deliver increased transparency, accountability, and innovation in their drug-development process while staying in budget. Through strategic application of technology, Glemser is committed to helping their clients modernize their drug-development processes.

By automating some of the most time-consuming reporting — such as Clinical Safety Reports (CSRs), Compliance Reports, Adverse Event Detection, and other regulatory reports — firms can reap cost savings and free their medical writers from the tedious work that is most prone to human error. Faster reporting means they can present findings to regulatory authorities more quickly. Improved accuracy early on in the reporting process means better compliance and faster regulatory approval.

“We are in a crucial moment, given today’s world events, when pharmaceutical companies’ ability to increase efficiencies and speed to market is more important than ever,” said Sharon Daniels, CEO of Arria. “Our collaboration with Glemser is a path to expedite decision-making and time to insights for those companies working to bring life-saving treatment to patients faster.”

Learn more

ABOUT ARRIA
Arria is the global leader in Natural Language Generation (NLG)—which transforms structured data into natural language. Through algorithms and modeling, Arria software replicates the human process of expertly analyzing and communicating data insights—dynamically turning data into written or spoken narrative—at machine speed and massive scale.

Arria has the greatest concentration of NLG expertise in the world and has a growing patent portfolio of 28 core NLG patents. Arria’s rapidly growing group of major international enterprise clients — including banking, financial services, insurance, pharmaceutical, consumer product goods, news and media — are now deploying NLG-driven automated reporting within their global organizations using Arria’s NLG Studio Platform. Additional information is available at www.arria.com.

Media Contact: Lyndsee Manna
Senior Vice President, Business Development and Partnerships
Lyndsee.manna@arria.com

Photo – https://techent.tv/wp-content/uploads/2020/05/glemser-technologies-and-arria-nlg-announce-strategic-partnership.jpg 
Logo – https://techent.tv/wp-content/uploads/2020/05/glemser-technologies-and-arria-nlg-announce-strategic-partnership-1.jpg

PR Newswire

VeChain and I-Dante Partnered to Create Blockchain Enabled Medical Data Management Platform for Healthcare Provider in Cyprus

Leave a comment

SHANGHAI, May 18, 2020 /PRNewswire/ — With more than 4.6 million infections, 300 thousand deaths and counting caused by COVID-19, national governments, healthcare systems regardless of region and continent have been scrambling to respond to it, and the pandemic has highlighted the increasing demand for digital technologies to replace our old way of communication. VeChain is at the frontier of this digital transformation, solving the problems of the management of healthcare data by utilizing solutions powered by blockchain technology.

With the aim of enabling digital transformation in the healthcare sector, VeChain, together with I-Dante co-developed a blockchain-enabled medical data management platform named The E-NewHealthLife. Mediterranean Hospital of Cyprus, a hospital under the General Healthcare System of the Republic of Cyprus (GHS) is the first hospital to adopt this application.

Healthcare System Advancement
 There have been efforts to modernize the technological infrastructure in the healthcare sector, but the problems include the administrative and technical difficulties of pooling data from different digital systems, the increasing cost, and the balance of health imperatives and privacy concerns, have greatly hampered the efforts. This dilemma has led to an urgent need for a low-cost yet highly-efficient digital solution.

With proven advantages in terms of secured data storage and efficient information sharing between multiple parties, blockchain technology has emerged as the best option in hand.

Blockchainized Actions In Response To The Challenges
There is a strong and urgent demand to deliver better and more efficient healthcare solutions that can achieve excellent patient-centric healthcare provision, secured data sharing, while complying with regulations on the use and sharing of patient data, which is solved in this case by the introduction of the E-NewHealthLife Web App in the Emergency Department of the hospital as the first phase of this project.

Powered by VeChain ToolChainTM, the Digital Healthcare Passport is an encrypted NFC Card that can be assigned to any patient of the hospital. The NFC Cards will allow the patients to identify themselves automatically at the Emergency Room registration desk, check their queue on mobile phone, manage their own medical records safely with the E-NewHealthLife Web App.

The blockchain powered application can serve both the hospitals internally and also end users. As The E-NewHealthLife fully complies with the GDPR (EU’s General Data Protection Regulation), the App enables the owner to have complete control over their profile and medical records. Data can only be shared to 3rd parties with the permission of the owner.

Bridging Trust In The Healthcare Sector
 Blockchain is being posited as the next frontier in healthcare that will help solve the industry’s interoperability challenges. According to a report by BIS Research, the global healthcare market spending and investment on blockchain-based technologies is expected to hit $5.61 billion by 2025. The adoption of blockchain technology could save the healthcare industry up to $100–$150 billion per year by 2025.

Based on concrete cases of multi party collaboration in various industries, VeChain has been accumulating experience in bridging trust and bringing in transparency into business while being compliant with local authorities and regulators. Given the huge potential of blockchain technology in the medical and healthcare sector, VeChain will continue to develop solutions for all stakeholders and pursue more opportunities in the near future.

About Mediterranean Hospital of Cyprus

The Mediterranean Hospital of Cyprus is a modern private health care institution, one of the largest in Cyprus, with a mission to provide to all the citizens and the visitors of the country safe and high quality medical services 24/7. The founder of the Mediterranean Hospital of Cyprus, Dr. Andreas Panayiotou has set as a goal the development and the establishment of a reliable infirmary, with flexible operational mechanisms, in order to gain the trust and recognition for the quality of its services from everybody. Mediterranean Hospital of Cyprus is the first private hospital that joined Cyprus’ General HealthCare System (GHS).

Website: www.medihospital.com.cy/en/

About I-DANTE LTD

Founded in December of 2019 by Etna Digital Growth (a consultancy- software house company in Italy) and CircleServus LTD (a consultancy company in Cyprus) in order to build digital healthcare solutions leveraging the power of the VeChainThor Blockchain.

Website: www.i-dante.com/

About VeChain

Launched in 2015, VeChain connects blockchain technology to the real world by providing a comprehensive governance structure, a robust economic model, and IoT integration. VeChain is the pioneer of real-world applications using public blockchain technology, with international operations in Singapore, Luxembourg, Tokyo, Shanghai, Paris, Hong Kong, and San Francisco. Together with our strategic partners PwC and DNV GL, we have established cooperative relations with many leading enterprises in different industries, including Walmart China, BMW, BYD Auto, Haier, H&M, LVMH, D.I.G, ENN, AWS, PICC, ASI etc.

Website: www.vechain.com 

Photo – https://techent.tv/wp-content/uploads/2020/05/vechain-and-i-dante-partnered-to-create-blockchain-enabled-medical-data-management-platform-for-healthcare-provider-in-cyprus.jpg

Logo – https://techent.tv/wp-content/uploads/2020/05/vechain-and-i-dante-partnered-to-create-blockchain-enabled-medical-data-management-platform-for-healthcare-provider-in-cyprus-1.jpg